Nov 22 (Reuters) - The U.S. Food and Drug Administration has approved BridgeBio's (BBIO.O), opens new tab drug for a rare and ...
The global over-the-counter (OTC) pain medication market is poised for steady growth, with its market size expected to attain ...
Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for ...
Rather than bribing and wheedling physicians to pretty-please-prescribe-our-drug, websites allow companies to deal drugs ...
Pfizer said the green light makes Hympavzi the first once-weekly subcutaneous treatment in the European Union for people with severe hemophilia B and the first to be administered via a pre-filled pen ...
The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years ...
Pfizer acquired Global Blood Therapeutics ... in addition to other debilitating symptoms caused by the medication including pain and swelling. While on the drug, the plaintiff suffered a stroke ...
Key drugs in shortage include ADHD medications, pain treatments ... Fresenius Kabi, Hikma, Pfizer, and Piramal Critical Care. Conversely, Fresenius Kabi, Hikma, and Pfizer continue to face ...
Pfizer has won European Commission approval of ... or syringe for those with severe hemophilia A or B. The U.S. Food and Drug Administration approved Hympavzi in October.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback